Filing Flows › Axsome Therapeutics (AXSM) › Product revenue
Axsome Therapeutics (AXSM) Product revenue by quarter
Axsome Therapeutics' Product revenue was $250M in Q3 2026 (third quarter 2026), +16% from Q2 2026. Over the last 6 quarters it ranged from $120M (Q1 2025) to $250M (Q3 2026).
| Quarter | Product revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $250M | +16% | +47% |
| Q2 2026 | $216M | +14% | +45% |
| Q1 2026 | $189M | +12% | +57% |
| Q3 2025 | $170M | +14% | — |
| Q2 2025 | $149M | +24% | — |
| Q1 2025 | $120M | — | — |
Q3 2026 at a glance
Axsome Therapeutics, Q3 2026: revenue $260M (+52% year over year), operating margin -4.3%, net loss $12.9M, operating cash flow −$9.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Axsome Therapeutics' Product revenue?
Axsome Therapeutics' Product revenue was $250M in Q3 2026 (third quarter 2026), +16% from Q2 2026.
How has Axsome Therapeutics' Product revenue changed?
Over the last 6 quarters it ranged from $120M (Q1 2025) to $250M (Q3 2026).